Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $0 versus the consensus estimate of $775 thousand.

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q
• Agnico Eagle subsidiary adds to Canada Nickel stake via private placement